الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 104 |  |  |
| | | from | 104 | | |
Abstract
SUMMARY
MD is the leading cause of severe impairment of visual function in people older than 50 years of age in industrialized countries. Choroidal neovascularization (CNV), the hallmark of ’wet’, ’exudative’ or ’neovascular’ AMD, is responsible for approximately 90% of cases of severe vision loss due to AMD.
The advent in OCT technology allows for early detection, and classification of neovascular AMD. Many studies used different OCT models to predict treatment response, and visual acuity after anti-VEGF injection.
This cross sectional, observational, non-randomized study included 33 eyes of 26 patients. Their age ranged from 50-80 years old. The study population was divided into; Neovascular AMD group: included 23 eyes of 20 patients with wet AMD (in the form of CNV). This group was further divided according to activity (the presence of subretinal / intraretinal fluid) into two groups; Active AMD group consisting of (13 eyes) of 10 patients with active CNV, and Inactive AMD group consisting of (10 eyes) of 10 patients with inactive CNV.
Control group was added and contained (10 eyes) of 6 healthy persons with no history of systemic or ocular disease affecting vision.
All cases underwent a complete ophthalmic examination including; history, refraction, best corrected visual acuity, slit lamp examination, fundus examination, and Optical coherence tomography, using Avanti RTVue XR AngioVue (Optovue Inc, Fremont, USA). Data was recorded in the form of; Age, BCVA (in Decimal, and LogMAR), central foveal thickness, and subfoveal choroidal thickness in all studied groups.
The mean age of healthy control group was 69+7.59 years old, while in active CNV group, the average age was 72.58+ 8.01 years old versus 74.8+ 5.25 years old in the inactive CNV group. Males were predominant in all groups (83.3 %, 58.33%, and 60% in control, active CNV and inactive CNV groups respectively). This difference was statistically insignificant.
The mean BCVA in decimal was 0.93+0.12 in control group (approximately 6/6, and 0.04+0.06 LogMAR), which was better than active CNV group (0.28+0.26 in decimal, approximately 6/24 and 0.86+0.64 LogMAR) and inactive CNV group (0.27+0.23 approximately 0.71+0.40 in LogMAR). The difference between three groups was statistically significant [P value < 0.001].
The mean central foveal thickness in control group was 205.3+ 15.5 um. While central foveal thickness in the active CNV group was 253.54+ 155.8 µm versus 248.5+97.94 µm in the inactive group. The difference was statistically insignificant [P value = 0.56].
Subfoveal choroidal thickness (SFCT) was significantly thinner in the inactive CNV group and active CNV than the control groups (136.40+72.97 µm, 179.23+64.36 µm, 270.1+59.5 µm respectively) [P value < 0.001].
No statistically significant difference in subfoveal choroidal thickness was found between active and inactive groups [P value =0.19].
There was no statistically significant correlation between central foveal thickness and BCVA in LogMAR neither in the active, inactive CNV groups. Also, no statistically significant correlation between BCVA in Log MAR and SFCT neither in the active group [P value 0.62], in the inactive group [P value 0.78]. Furthermore, no statistically significant correlation was found between CFT, and SFCT.
Finally we concluded a significant thinning of choroid in nAMD in comparison to control. But there was no statistically significant difference in subfoveal choroidal thickness between active and inactive choroidal neovascular groups